Why is LENZ down?
Down 89% in a year while the S&P 500 rose 7%.
- Its loss grew from $49.8M in fiscal 2024 to $82.1M in fiscal 2025.
−3Long-term trend
Down 89% in a year while the S&P 500 rose 7%.
−3Long-term trend
LENZ's Quality Score fell 2 points on Fri, Nov 20, to -11. It closed away from its high of the day (2 chart checks stopped).
Follow LENZ's news. Pro members can get an alert when LENZ Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 12.2% a day with no profit behind it |
| Its score | Down:Lowest Quality Score since May 2024 |
| Latest filing | 10-Q, Nov 3 |
LENZ Therapeutics filed an 8-K reporting a change of CEO
LENZ closed −12.6% that day on 2.8x normal volume.
After its last 4 reports it closed -8.3% on average, higher 1 of 4 times.
About 6 quarters
Director Jeffrey P. George bought 5,592 shares on Mar 27. 2 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
LENZ is #269 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 269 |
Expected to report Tue Mar 23, after the close (in 122 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $3.4M, 73% less than a year ago; a loss of $0.99 a share, from $0.59.
“These increases were primarily driven by our launch investment, with increases in commercial marketing, advertising, sales infrastructure, and personnel-related expenses due to a growth in headcount.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $2.6M | $1.7M | – |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
| Measure | Figure |
|---|---|
| Operating expenses | $70M to $75M |
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | -6.5% | +8.7% | +7.8% |
| Aug 11, 2026 | +13.8% | -3.3% | -8.4% |
| May 11, 2026 | -23.1% | -20.8% | -30.9% |
Sales grew in 2025, to $19.1M. It lost money in both years.
RSI 39.2, MACD below signal, below both averages. Not scored.
One insider sold $9.1M across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: LENZ is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
“The biotechnology, pharmaceutical, and ophthalmology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property.”
LENZ scores -11 today, which Breakaway calls Poor. It is #269 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 89% in a year while the S&P 500 rose 7%. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
LENZ scores -11 today, which Breakaway calls Poor (below zero). That is #269 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LENZ's -11.
One insider sold $9.1M across 3 filings in the last 6 months. No open-market buys on record. The newest is RA Capital Management, L.P., 10% owner, who sold $7.3M on Oct 29. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.